Incyte Corporation (LON:0J9P)
67.45
-1.16 (-1.70%)
At close: Jul 7, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
JAKAFI | 2.79B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
JAKAFI Growth | 13.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
JAKAVI Product Royalty | 418.84M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
JAKAVI Product Royalty Growth | 10.75% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Milestone and Contract | 43.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Milestone and Contract Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ICLUSIG | 114.32M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ICLUSIG Growth | -0.67% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
OLUMIANT Product Royalty | 135.57M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
OLUMIANT Product Royalty Growth | 2.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PEMAZYRE | 81.75M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PEMAZYRE Growth | 4.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
TABRECTA Product Royalty | 22.75M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
TABRECTA Product Royalty Growth | 26.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
OPZELURA | 508.29M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
OPZELURA Growth | 47.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
MINJUVI | 119.24M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
MINJUVI Growth | 129.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Royalty | 2.17M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Royalty Growth | 37.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ZYNYZ | 3.19M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ZYNYZ Growth | 233.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|